CNS Pharmaceuticals, a biotechnology company specializing in the development of novel treatments for brain tumors, said that Anthem Biosciences of Bangalore, India has completed a pilot run of the recrystallization of the Reata Pharmaceuticals’ active pharmaceutical ingredient (API). It has also completed a lyophilization of the API. Samples of the drug product, which include 299 capped vials, have been shipped to Intertek Pharmaceutical Services for further analysis and release.   As previously...